Related Experiment Videos
Neoadjuvant chemotherapy for operable breast cancer
Marjorie Green1, Gabriel N Hortobagyi
1Department of Breast Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston 77030-4009, USA. mgreen@mdanderson.org
Oncology (Williston Park, N.Y.)
|August 8, 2002
Summary
Neoadjuvant chemotherapy for operable breast cancer shows promise for breast conservation but has not yet demonstrated a survival advantage over standard adjuvant chemotherapy. Further research is ongoing.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Adjuvant systemic chemotherapy improves survival in breast cancer patients.
- Neoadjuvant chemotherapy enhances breast-conserving therapy rates in locally advanced breast cancer.
- Preclinical data and laboratory studies support neoadjuvant chemotherapy investigation.
Purpose of the Study:
- To review evidence supporting neoadjuvant chemotherapy for operable breast cancer.
- To discuss challenges associated with the neoadjuvant approach.
- To evaluate the efficacy and safety of neoadjuvant chemotherapy.
Main Methods:
- Analysis of seven completed randomized studies comparing neoadjuvant chemotherapy followed by surgery versus surgery followed by adjuvant chemotherapy.
- Review of preclinical evidence and laboratory findings.
- Evaluation of data from recent phase III trials.
Main Results:
- No trial has demonstrated a survival advantage for neoadjuvant chemotherapy compared to adjuvant chemotherapy.
- Neoadjuvant chemotherapy has improved rates of breast-conserving surgery.
- Neoadjuvant chemotherapy has not been found to be harmful to patients.
Conclusions:
- Neoadjuvant chemotherapy is a validated treatment option for operable breast cancer.
- While not yet showing a survival benefit, its role in improving surgical outcomes is recognized.
- Ongoing research and recent phase III trials support its continued use.